Diffuse large B cell lymphomas (DLBCLs) arise from proliferating B cells transiting different
stages of the germinal center reaction. In activated B cell DLBCLs (ABC-DLBCLs), a class of …

BH3 mimetics are a new class of proapo-ptotic anticancer agents that have shown
considerable promise in preclinical animal models and early-stage human trials. These …

The BCL-2/BCL-XL/BCL-W inhibitor ABT-263 (navitoclax) has shown promising clinical
activity in lymphoid malignancies such as chronic lymphocytic leukemia. However, its …

Since apoptosis is impaired in malignant cells overexpressing prosurvival Bcl-2 proteins,
drugs mimicking their natural antagonists, BH3-only proteins, might overcome …

DNA polymerase theta (POLθ or POLQ) is synthetic lethal with homologous recombination
(HR) deficiency and is thus a candidate target for HR-deficient cancers. Through high …

Proteolysis Targeting Chimeras (PROTACs) are attractive therapeutic modalities for
degrading disease-causing proteins. While many PROTACs have been developed for …

Overexpression of the prosurvival Bcl-2 family members (Bcl-2, Bcl-xL, and Mcl-1) is
commonly associated with tumor maintenance, progression, and chemoresistance. We …

Antibody and chimeric antigen receptor (CAR) T cell-mediated targeted therapies have
improved survival in patients with solid and haematologic malignancies,,,,,,,–. Adults with T …

The emphasis in cancer drug development has shifted from cytotoxic, non-specific
chemotherapies to molecularly targeted, rationally designed drugs promising greater …

The BCR–ABL fusion oncoprotein causes chronic myeloid leukemia or acute lymphoblastic
leukemia in Ph+ patients because the ABL kinase is constitutively activated. However …